|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001807,
umls-concept:C0017262,
umls-concept:C0017636,
umls-concept:C0021701,
umls-concept:C0185117,
umls-concept:C0231491,
umls-concept:C0330390,
umls-concept:C0379710,
umls-concept:C0851285,
umls-concept:C1741686,
umls-concept:C2003941,
umls-concept:C2587213,
umls-concept:C2911684
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2009-1-26
|
|
pubmed:abstractText |
Caveolin-1 plays a checkpoint function in the regulation of processes often altered in cancer. Although increased expression of caveolin-1 seems to be the norm in the glioma family of malignancies, populations of caveolin-1 positive and negative cells coexist among glioblastoma specimens. As no data are available to date on the contribution of such cells to the phenotype of glioblastoma, we manipulated caveolin-1 in the glioblastoma cell line U87MG. We showed that caveolin-1 plays a critical role in the aggressiveness of glioblastoma. We identified integrins as the main set of genes affected by caveolin-1. We reported here that the phenotypic changes observed after caveolin-1 modulation were mediated by alpha(5)beta(1) integrins. As a consequence of the regulation of alpha(5)beta(1) levels by caveolin-1, the sensitivity of cells to the specific alpha(5)beta(1) integrin antagonist, SJ749, was affected. Mediator of caveolin-1 effects, alpha(5)beta(1) integrin, is also a marker for glioma aggressiveness and an efficient target for the treatment of glioma especially the ones exerting the highest aggressive phenotype.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0006-3002
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
1793
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
354-67
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:18992284-Caveolin 1,
pubmed-meshheading:18992284-Cell Adhesion,
pubmed-meshheading:18992284-Cell Line, Tumor,
pubmed-meshheading:18992284-Cell Movement,
pubmed-meshheading:18992284-Cell Proliferation,
pubmed-meshheading:18992284-Gene Expression Profiling,
pubmed-meshheading:18992284-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:18992284-Glioblastoma,
pubmed-meshheading:18992284-Humans,
pubmed-meshheading:18992284-Integrin alpha5beta1,
pubmed-meshheading:18992284-Mitogen-Activated Protein Kinases,
pubmed-meshheading:18992284-Neoplasm Invasiveness,
pubmed-meshheading:18992284-Neoplasm Metastasis,
pubmed-meshheading:18992284-Phenotype,
pubmed-meshheading:18992284-Plasminogen Activator Inhibitor 1,
pubmed-meshheading:18992284-Propionic Acids,
pubmed-meshheading:18992284-Pyridines,
pubmed-meshheading:18992284-Spiro Compounds,
pubmed-meshheading:18992284-Tumor Stem Cell Assay
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Caveolin-1 regulates glioblastoma aggressiveness through the control of alpha(5)beta(1) integrin expression and modulates glioblastoma responsiveness to SJ749, an alpha(5)beta(1) integrin antagonist.
|
|
pubmed:affiliation |
Université Strasbourg 1 Institut Gilbert Laustriat, CNRS UMR 7175, Illkirch, France. Sophie.Martin@pharma.u-strasbg.fr
|
|
pubmed:publicationType |
Journal Article
|
